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 Abstract 
Pulmonary arterial hypertension (PAH) is a rare cardiovascular disorder caused by 
narrowing of blood vessels in the lung and in the absence of therapy leads to right heart 
failure and death.  No cure for this devastating disorder is known. The major objective of 
the current treatments is to improve symptoms and these therapies were developed 
prior to the discovery that this disease has substantial genetic components. In this 
review, we discuss molecular genetic basis of PAH together with pathobiology, current 
and future therapeutic interventions.  
Introduction 
Pulmonary arterial hypertension (PAH) is a rare cardiovascular disorder characterised 
by the sustained elevation of blood pressure in pulmonary arteries, recorded above 25 
mm of Hg during rest and 30 mm of Hg during exercise[1]. The rise in the pressure 
occurs due to occlusion of pulmonary arteries in the lungs leading to subsequent right 
heart failure and death, if left untreated. It is estimated that approximately 146,000 
subjects suffer from this devastating disease across the EU, USA and Japan (see 
www.leaddiscovery.co.uk/reports/424/PulmonaryArterial_Hypertension). Although the 
cases of PAH have been reported in India, Pakistan and Bangladesh yet a lack of 
epidemiology accounts for the unavailability of PAH patients in the Indian 
subcontinent[2].  
The underlying mechanisms of the pathogenesis of PAH remain unknown. However, 
many investigations support the role of a cell surface receptor, bone morphogenetic 
protein receptor 2 (BMPR2) in development and progression of PAH[3], as germline 
mutations have been identified in the majority of patients with a family history. 
Moreover, PAH has been shown to occur in correlation with other pathological condition 
such, scleroderma, portal hypertension and hereditary haemorrhagic telangiectasia and 
infection of HIV[4], HHV[5], Hepatitis Virus B and C[6-7]. Environmental factors such as 
hypoxia[8] and chemical like monocrotaline[9], appetite suppressor drugs 
anorexigens[10] and nerve cell stimulants like methamphetamine and cocaine[11] have 
also been shown to play a role in the disease pathogenesis.  Monocrotaline and hypoxia 
have been used to induce the disease in model organisms including mouse and rat. 
PAH is caused by the obstruction of pulmonary arteries due to excessive proliferation of 
cells in tunica intima, tunica media and tunica adventitia along with deposition of 
components of extracellular matrix. The formation of occlusive lesion initiates in the 
tunica media, called as medial thickening, as the pulmonary arterial smooth muscle 
cells (PASMCs) start to proliferate. Medial thickening is followed by the proliferation of 
endothelial cells and transitional cells in the tunica intima and fibroblasts in the tunica 
adventitia. Intimal thickening occurs in two phases, initially myofibroblast like cells, 
originating from the PASMCs, migrate to the endothelial lining and start dividing and 
then the collagen deposition occurs. However, in the most severe occlusions, plexiform 
lesions are formed by the proliferation of endothelial cells and multiple capillary 
channels. The thickening in adventitia occurs due to proliferation of fibroblast cells that 
are sensitive to stimuli like hypoxia, monocrotaline treatment and high perfusion blood 
flow.    
In this review we aim to understand the molecular basis of current therapies and how 
the genetic basis of PAH is likely to change the conventional therapeutic approaches.  
 
Molecular basis of current therapies  
The current therapies for PAH are based primarily on vasoeffectors, a set of molecules 
that controls the blood flow in the vasculature. They could either dilate the blood vessels 
by relaxing the PASMCs or constrict the blood vessels by contracting them. The former 
are vasodilators and the latter are referred as vasoconstrictors. They also control the 
proliferation of PASMCs and activation of platelets. Human body maintains a 
physiological balance between the dilators and constrictors and thus the imbalance 
plays vital role in PAH pathogenesis.   (review in [12]). Almost all the vasoeffector 
molecules have been shown at aberrant levels in PAH (Table 1).  
Since, understanding of the disease pathogenesis was based on vasoeffector 
molecules, the first drug for PAH, approved in 1996, was a prostacyclin analogue - 
Epoprostenol[13]. Many drugs followed that targeted particular vasoeffector molecules, 
particularly NO, serotonin and endothelin (Table 2).   Depending upon the role of the 
vasoeffector, the compound aimed at increasing or decreasing its activity by targeting 
the vasoeffector molecule itself, its receptors or the synthesis pathways. For example, 
most of the endothelin inhibitors target the endothelin receptor and the NO based drugs 
aim at inhibiting the PDE-5 receptors and increasing the level of cGMP and  increasing 
NO bioavailability by targeting the synthesis of the enzyme endothelial nitric oxide 
synthase – eNOS. Sildenafil Citrate, sold under trade name REVATIO by Pfizer, 
reduces degradation of  cGMP by inhibiting PDE-5[14]. 
Though the approach discussed above appears to be simpler, but the compounds in 
question only improve the symptoms. They do not target the underlying cause of PAH. 
Most of these compounds have shown side effects including nausea, headache and 
oedema. Some of these drugs have shown to affect the metabolism of the liver. It has 
been shown that bosentan increased the level of liver enzymes, aspartate 
aminotransferase or alanine aminotransferase[15]. Similarly, Sitaxsentan has been 
withdrawn by Pfizer due to  the adverse side effects on pregnancy and impairment of 
lactations[16]. 
 
Molecular genetic basis of PAH 
Heterozygous mutation in the BMPR2 gene underlies the majority of the inherited and 
familial forms of PAH. Mutations are also found in SMAD genes namely SMAD1, 4 and 
9 but they represent an infrequent cause of the disease[17]. Dysfunctional BMPR-II or 
SMAD-mediated signalling potentiates the TGF-beta signalling. Increasing number of 
studies suggest the involvement of TGF signaling in PAH. In vitro, TGF-β1 elicits a 
pro-proliferative response in PASMCs isolated from PAH patients (PAH-PASMCs) 
compared to controls [18]. Elevated TGFβ signaling has been implicated in a number of 
preclinical PAH models, including the aorto-pulmonary shunt model in lambs [19], 
hypoxia-induced PAH in mice and the monocrotaline (MCT)-induced model in rats [20]. 
 The TGFβ family of ligands convey signalling through a complex of two cell surface 
receptors, type-I and type-II. On binding the appropriate ligand, the type-I receptor (also 
known as ALK) phosphorylates the type-II receptor. Subsequently, the type-II receptor 
phosphorylates a set of cytoplasmic proteins known as regulatory SMAD (R-SMADs). 
Activated R-SMADs form a complex with co-SMAD and translocates to the nucleus, 
where they regulate transcription.  
Both, TGF-β and BMP mediated signalling are instrumental for the maintenance of 
cellular homeostasis. They are involved in differentiation and development and control 
both proliferation and differentiation of PASMCs and endothelial cells.  Although, 
nonsense mutations in the BMPR2 gene have been discovered as the major genetic 
determinant in familial PAH[21], yet the cause of the aberration in TGF-β signalling is 
not well understood. A linking protein called TGF-β associated kinase 1 (TAK1) has 
been proposed as one of the key determinant as inhibition of this protein inhibited 
excessive PASMC proliferation [22]. TAK1 seems to be interacting with both BMP and 
TGF-β receptors and in the event of BMPR2 mutation identified in PAH patients, the 
BMP receptor is not able to take as much as TAK1 as the wild type receptor. This 
makes TAK1 accessible to TGF-β receptor which elicits pro-proliferative activity.   
 
Therapeutic resolution based on the genetics of PAH   
Although gene therapy has been proposed for the treatment of many genetic disorders, 
yet development of suitable vectors remains a big challenge. Most of these vectors are 
virus based and the subjects need to be immune-compromised and hence this route is 
far from achieving routine clinical success.  
Antibiotic compounds such as aminoglycosides and several small molecule compounds, 
including oxadiazole compound PTC124[23], acetyl-amino benzoic acid derivatives[24] 
and nitrobenzene compounds RTC13/14[25], have proposed as a therapeutic strategy 
for the treatment of nonsense associated genetic diseases including cystic fibrosis and 
Duchene muscular dystrophy as these compounds have been shown to promote 
translation readthrough of nonsense alleles. Promotion of readthrough in PAH-related 
cell-based studies [26-27] suggests that agents that promote translation readthrough of 
BMPR2 nonsense alleles may be therapeutically beneficial.  
Another strategy for the resolution of PAH appears to be the inhibition of TGF-β 
signalling. Inhibition of TGF-β signalling in both monocrotaline and hypoxia induced 
animal models by known inhibitor of ALK-5 has reduced excessive PASMC proliferation 
and also reversed muscularisation of pulmonary arteries[28]. However, targeting this 
pathway carries substantial risk due to its role in maintaining normal homeostasis. 
Therefore, the inhibition of this pathway requires a deeper understanding of TGF- 
signaling and the context in which it acts, as well as the cellular consequences of its 
inhibition.  
 
Conclusion 
 
Until recently, PAH has been considered to be a highly progressive disorder, resulting 
death in many cases. However, the impact of BMPR2 gene mutations and the 
involvement of the aberrant TGF-β signalling in the disease pathogenesis has opened 
new avenues for developing therapies for this devastating disease. Drugs that inhibit the 
overactive TGF-β signalling or resolve the biochemical consequences of BMPR2 gene 
defects could potentially provide protection prior to or following the onset of PAH.  
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